Related Experiment Video

Updated: Aug 9, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas

Yasuo Adachi1, Chieko Aoki, Naoko Yoshio-Hoshino

  • 1Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan.

International Journal of Cancer
|April 28, 2006
PubMed

Insights

Interleukin-6 (IL-6) acts as an autocrine growth factor in malignant mesothelioma (MM). Blocking IL-6 signaling with an anti-IL-6 receptor antibody suppressed MM cell growth, suggesting a potential targeted therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Malignant mesothelioma (MM) is an aggressive, incurable cancer.
  • Interleukin-6 (IL-6) is known to be secreted by MM tumors, but its role is unclear.
  • Understanding IL-6's function is crucial for developing novel MM therapies.

Purpose of the Study:

  • To investigate the biological functions of IL-6 in malignant mesothelioma.
  • To determine if IL-6 acts as an autocrine growth factor in MM.
  • To explore the potential of targeting the IL-6 pathway for MM treatment.

Main Methods:

  • Analyzed IL-6 production and IL-6 receptor (IL-6R) expression in five MM cell lines.
  • Used recombinant soluble IL-6R (sIL-6R) to mediate IL-6 signaling in low IL-6R expressing cells.
  • Treated cells with IL-6/sIL-6R and an anti-IL-6R antibody (MRA); assessed cell growth and vascular endothelial growth factor (VEGF) expression.
  • Investigated the involvement of the signal transducer and activator of transcription 3 (STAT3) pathway.

Main Results:

  • IL-6, in combination with sIL-6R, promoted dose-dependent cell growth in high IL-6 producing MM cell lines (H2052, H226).
  • Anti-IL-6R antibody (MRA) suppressed IL-6/sIL-6R-induced MM cell growth.
  • IL-6/sIL-6R stimulation increased VEGF expression in most cell lines, an effect inhibited by MRA.
  • The STAT3 pathway was involved in IL-6/sIL-6R-mediated cell growth and VEGF induction.
  • Anti-VEGF antibodies did not inhibit IL-6-induced cell growth, indicating IL-6-dependent growth is independent of VEGF induction.

Conclusions:

  • Interleukin-6 (IL-6) functions as an autocrine growth factor in malignant mesothelioma.
  • Targeting the IL-6 receptor with antibodies (e.g., MRA) shows promise for MM therapy.
  • IL-6 signaling contributes to MM progression through pathways independent of VEGF induction.

More Related Videos

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...